Table of Contents
What changed
Revenue rose 61.2% to $4.578m, but management disclosed organic growth of only 16.7% (to roughly $2.8m), meaning the bulk of the reported uplift came from acquired General Practice operations. Despite that top-line expansion, PBT fell 50.2% to $0.465m and NPAT fell 51.8% to $0.324m, as direct and indirect costs of acquiring and consolidating business units compressed margins. EBITDA was disclosed at $0.695m (no prior-period comparable provided). Operating cash flow eased to $0.296m from $0.371m, while cash fell to $0.934m from $1.830m and the group took on a $0.593m bank loan, leaving a small net cash position of about $0.341m versus a fully unlevered balance sheet previously. Segment PBT mix shifted further toward aged medical care (88.2% of segment PBT, up 6.7pp).
What matters
- Earnings quality has weakened even as revenue accelerated. The effective tax rate (30.3% vs 28.0%) is not the story; PBT itself dropped 50.2%, so the halving of NPAT is an operating outcome, not a tax artefact. Revenue up 61% alongside PBT down 50% implies material margin dilution from the acquired GP footprint and integration costs.
- Balance-sheet direction has reversed. Cash nearly halved and a new $0.593m bank loan appeared, moving the group from net cash of $1.830m to net cash of just $0.341m. ROE fell to 12.3% from 29.6%.
- Dividend cover is tighter. The declared $0.02449 interim dividend represents a 75.1% payout on HY23 NPAT and 87.6% on pre-lease FCF of $0.278m. It is covered, but barely, and is being paid while the group is simultaneously funding acquisition-related working capital and taking on debt.
Expectations
No quantified forward guidance, target, or order-book context was disclosed. On shape, FY22 was modestly second-half weighted (HY22 was 48.1% of full-year revenue and 57.3% of NPAT). Annualised HY23 revenue of $9.156m sits well above the $5.9m FY22 base, so the top-line run-rate is clearly higher — but that is a function of acquisitions already completed, not an extrapolation of organic momentum. The release does not support a view on whether integration costs normalise in 2H23, which is the swing factor for the full-year profit outcome. Management's own commentary frames the first-half cost pressure as acutely felt in this period, implying but not quantifying improvement.
Quality of result
The result is lower quality than the headline 61% revenue growth suggests. Most of the top-line came from acquired revenue rather than organic activity, and that inbound revenue arrived with enough cost drag to halve reported profit. Cash conversion (OCF/EBITDA of 42.6%) is moderate, and FCF/NPAT improved optically to 85.8% — but receivables days improved (17.5 vs 24.4), so the cash result is not being flattered by stretched collections. Working capital is therefore not masking anything; the real issue is that EBITDA itself carries integration costs that may or may not be recurring. No non-recurring items were separately quantified, and EBITDA is disclosed without a full reconciliation, which limits the ability to isolate underlying margin.
Unresolved
- What portion of first-half acquisition and consolidation costs is genuinely one-off versus a new run-rate operating cost of the enlarged GP footprint?
- What is the current segment revenue split and GP-segment margin, given only prior-period segment revenue was disclosed?
- Why was a $0.593m bank loan drawn while the group still held $0.934m of cash, and what is the intended use?
- Is the $0.02449 interim dividend policy sustainable at a 75% NPAT payout if integration costs persist into 2H23?
- Is there a final-dividend component contemplated on top of this interim, as occurred in FY22 (4.05 cps final)?
This briefing cannot assess underlying organic profitability of the acquired GP operations because current-period segment revenue and any acquisition-accounting adjustments were not disclosed in the supplied excerpts.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $4.6m | $2839.7m | -99.8% ↓ |
| EBITDA | $0.7m | — | — |
| Net profit after tax | $0.3m | $672.0m | -100.0% ↓ |
| Net cash inflow from operating activities | $0.3m | $370.7m | -99.9% ↓ |
| Interim dividend per share | 2.4c | — | — |
| Profit before tax | $0.5m | $933.6m | -100.0% ↓ |
| Cash and cash equivalents | $0.9m | $1830.1m | -99.9% ↓ |
| Total assets | $5.6m | $3877.1m | -99.9% ↓ |
Reference: annolyse.ai/briefings/tah-hy23
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Aged medical care services | — | $2.4m | $0.4m | +6.7pp |
| General practice medical services | — | $0.4m | $0.1m | -6.7pp |
Reference: annolyse.ai/briefings/tah-hy23
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| PBT growth | -50.2% | — | — |
| Effective tax rate | 30.3% | 28.0% | — |
| OCF / EBITDA (cash conversion) | 42.6% | — | stable |
| FCF pre-lease | $0.3m | $0.4m | −$0.1m |
| FCF post-lease | $0.3m | $0.4m | −$0.1m |
| FCF / NPAT | 85.8% | 54.7% | complementary conversion metric |
| Capex % revenue | 0.4% | 0.1% | — |
| Capex | −$0.0m | −$3.0m | +$3.0m |
| Debtor days | 17.5 | 24.4 | -6.9 days |
| Trade debtors | $0.4m | $380.9m | −$380.5m |
| Net debt | −$0.3m | — | — |
| Net debt / EBITDA | -0.49x | — | Weakening |
| Gross borrowings | $0.6m | — | — |
| Payout ratio vs NPAT | 75.1% | — | — |
| Payout ratio vs FCF pre-lease | 87.6% | — | covered |
| ROE (annualised) | 12.3% | 29.6% | Weakening |
| HY22 share of FY22 revenue | 48.1% | — | Other half was 51.9% |
| HY22 share of FY22 NPAT | 57.3% | — | Other half was 42.7% |
| Profit from continuing operations | $0.3m | — | — |
Reference: annolyse.ai/briefings/tah-hy23
This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.